Related Experiment Video
Updated: Feb 27, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Antihypertensive Medication Adherence and Risk of Cardiovascular Disease Among Older Adults: A Population-Based
Quanhe Yang1, Anping Chang2, Matthew D Ritchey2
1Division for Heart Disease and Stroke Prevention, Centers for Disease Control and Prevention, Atlanta, GA qay0@cdc.gov.
Insights
High adherence to antihypertensive medication significantly reduces cardiovascular disease (CVD) risk in older adults. A threshold of 80% medication adherence shows a substantial reduction in CVD events.
Area of Science:
- Gerontology
- Cardiology
- Pharmacology
Background:
- Antihypertensive medication adherence is known to reduce cardiovascular disease (CVD) risk.
- Limited research exists on this association specifically within older adult populations.
Purpose of the Study:
- To investigate the relationship between antihypertensive adherence and CVD risk in older adults.
- To identify potential adherence thresholds for CVD risk reduction.
Main Methods:
- Analysis of Medicare fee-for-service beneficiaries (aged 66-79) newly diagnosed with hypertension.
- Calculation of proportion of days covered (PDC) for antihypertensives.
- Use of proportional subdistribution hazard models to assess CVD event risk.
Main Results:
- A total of 155,597 beneficiaries were included, with 47,198 CVD events documented over a median of 5.8 years.
- Crude CVD incidence was lowest for those with PDC ≥80% (40.1/1000 person-years).
- Adjusted hazard ratios showed significantly lower CVD risk for PDC ≥80% (0.44) compared to <40% (reference).
Conclusions:
- Antihypertensive adherence is strongly associated with a reduced risk of cardiovascular events in older adults.
- A significant protective effect against CVD events was observed at an adherence level of approximately 80% PDC.
- This suggests a threshold effect for medication adherence in mitigating CVD risk.
Background:
Antihypertension medication (antihypertensive) adherence lowers risk of cardiovascular disease (CVD); few studies have examined this association among older adults.
Methods And Results:
We assessed this association among Medicare fee-for-service beneficiaries aged 66 to 79 years who were newly diagnosed with hypertension and initiated on antihypertensives in 2008-2009 (n=155 597). We calculated proportion of days covered (PDC) during follow-up, using proportional subdistribution hazard models, to examine association between antihypertensive adherence and a composite CVD outcomes, including first incident of fatal/nonfatal acute myocardial infarction, ischemic heart disease, stroke/transient ischemic attack, and heart failure. During follow-up (median 5.8 years and 798 621 person-years), we documented 47 198 CVD events. Among beneficiaries, 60.8%, 30.3%, and 8.9% had PDC ≥80%, 40% to 79%, and <40%. Crude incidence of CVD events were 40.1 (95% CI, 40.0-40.1), 93.9 (93.8-93.9), and 98.1 (98.1-98.2) per 1000 person-years for PDC ≥80%, 40% to 79%, and <40%, respectively. Adjusted hazard ratios for CVD events were 1.0 (<40% as reference), 1.0 (0.97-1.03) for 40% to 79%, and 0.44 (0.42-0.45) for ≥80% (P<0.001). Dose-response analysis suggested a nonlinear relationship between PDC and risk for CVD events with a protective effect of ≥80%. The pattern of associations between PDC and ischemic heart disease, stroke/transient ischemic attack, and heart failure were largely consistent as for CVD events and across different groups.
Conclusions:
Antihypertensive adherence was associated with a significantly lower risk of CVD events among older adults. There appeared to be a threshold effect in reducing CVD events at around PDC 80%, above which the risk for CVD reduced substantially.
Related Concept Videos
Drug Dosing: Geriatric Patients
Hypertension IV: Drug Therapy and Lifestyle Modifications
Hypertension V: Nursing Management
Pharmacodynamics in Geriatric Patients: Effects of Age
Hypertension III: Clinical Manifestations and Diagnostic Studies
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution